tbuckley/cabot-search huggingface dataset:
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies
Authors: Boni E. Elewski, Raza Aly, Sheryl L. Baldwin, Remigio F. González Soto, Phoebe Rich, Max Weisfeld, Hector Wiltz, Lee T. Zane, Richard Pollak
Journal: Journal of the American Academy of Dermatology (2015)

BackgroundOnychomycosis, a fungal nail infection, can impact quality of life.ObjectiveWe sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of toenail onychomycosis.MethodsIn 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 weeks. The primary end point was complete cure of the target great toenail (completely clear nail with negative mycology) at week 52. Secondary end points included completely or almost clear nail, negative mycology, completely or almost clear nail plus negative mycology, and safety.ResultsRates of negative mycology (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole versus vehicle (P ≤ .001). Completely or almost clear nail rates also significantly favored tavaborole versus vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001). Rates of completely or almost clear nail plus negative mycology (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole versus vehicle (P < .001). Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).LimitationsDuration of follow-up is a limitation.ConclusionTavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis. Onychomycosis, a fungal nail infection, can impact quality of life. We sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of toenail onychomycosis. In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 weeks. The primary end point was complete cure of the target great toenail (completely clear nail with negative mycology) at week 52. Secondary end points included completely or almost clear nail, negative mycology, completely or almost clear nail plus negative mycology, and safety. Rates of negative mycology (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole versus vehicle (P ≤ .001). Completely or almost clear nail rates also significantly favored tavaborole versus vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001). Rates of completely or almost clear nail plus negative mycology (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole versus vehicle (P < .001). Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%). Duration of follow-up is a limitation. Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis.
The Causes of Hypertension
Authors: E. T. Bell, A. H. Pedersen
Journal: Annals of Internal Medicine (1930)

Article1 September 1930The Causes of HypertensionE. T. BELL, M. D., A. H. PEDERSEN, M. D.E. T. BELL, M. D.Search for more papers by this author, A. H. PEDERSEN, M. D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-4-3-227 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis paper deals with the various factors that regulate or influence blood pressure in health and disease. By a study of known processes we may approach the problem of primary hypertension.A. MECHANISMS CONCERNED IN THE REGULATION OF THE BLOOD PRESSURE.1.The heart. The energy required to maintain or elevate the systemic blood pressure is furnished by the contraction of the left ventricle. When the peripheral resistance is increased the blood pressure must be raised, if the tissues are to receive as much blood as they did before the increase of resistance occurred. When the tissues require more blood,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Minneapolis, Minnesota*Presented before the American College of Physicians, Minneapolis, Minnesota, February 11, 1930.†From the Department of Pathology, University of Minnesota, Minneapolis. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPharmacognosy and Effects of Cannabinoids in the Vascular SystemHypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alterationRenal arteriovenous fistula as a cause of hypertensionRenal Venous Thrombosis in ChildrenThrombosis of the Inferior Vena Cava and Hepatic Veins (Budd-Chiari Syndrome)MILTON R. HALES, M.D., JAMES H. SCATLIFF, M.D.Morphologische Spätveränderungen und nephrotisches Syndrom nach einseitiger Nierenvenendrosselung bei der RatteHypertonieMorphologische Spätveränderungen und nephrotisches Syndrom nach einseitiger Nierenvenendrosselung bei der RatteHypertonieKlinikExperimentelle und klinische Untersuchungen zur Frage der Hypertonie bei chirurgischen NierenerkrankungenHypertension in Unilateral Renal DiseaseThe effect of renal vein occlusion on the blood pressure of the dogHypertension Associated with Unilateral NephropathyHypertension’s Challenge to UrologyUrologic Hypertension: A Study or 101 CasesRelations Between Endocrinology and UrologyObservations on the genesis of renal hypertensionÜber ReninHypertension in Unilateral Renal Disease„Über das Renin”. Ein experimenteller Beitrag zur Pathogenese des renalen HochdrucksExperimental Hypertension and Retinal Arterial Spasm 1 September 1930Volume 4, Issue 3Page: 227-237KeywordsBloodBlood pressureHeartLeft ventriclePrimary hypertension ePublished: 1 December 2008 Issue Published: 1 September 1930 PDF downloadLoading ...
Dose-response effects of TPI ASM8 in asthmatics after allergen
Authors: G. M. Gauvreau, R. Pageau, R. Séguin, D. Carballo, J. Gauthier, H. D’Anjou, H. Campbell, R. Watson, M. Mistry, M. Parry-Billings, K. Killian, P. M. Renzi
Journal: Allergy (2011)

To cite this article: Gauvreau GM, Pageau R, Séguin R, Carballo D, Gauthier J, D'Anjou H, Campbell H, Watson R, Mistry M, Parry-Billings M, Killian K, Renzi PM. Dose–response effects of TPI ASM8 in asthmatics after allergen. Allergy 2011; 66: 1242–1248. Background: TPI ASM8 contains two modified antisense oligonucleotides (AON) targeting the beta subunit (βc) of the IL-3, IL-5, GM-CSF receptors and the chemokine receptor CCR3. A previous study suggested that TPI ASM8 had broader effects than just inhibition of eosinophils in asthmatics. Objective: We assessed whether TPI ASM8 caused a dose-dependent attenuation in the inflammatory and physiological changes after inhaled allergen challenge (AIC). Methods: This single-center, open-label, stepwise-ascending dose study was conducted in fourteen stable, mild allergic asthmatics. Following placebo AIC, subjects underwent AIC after 4 days treatment with 1, 2, and 4 mg BID and finally 8 mg once daily (OD) of TPI ASM8, inhaled via the I-Neb™ nebuliser. Treatments were separated by 2–3-week washout periods. Results: TPI ASM8 was safe and well tolerated at all doses. TPI ASM8 8 mg OD reduced eosinophils in sputum after AIC (by 60.9% at 7 h and 68.4% at 24 h post-AIC, P = 0.016 and P = 0.007, respectively). Additionally, TPI ASM8 8 mg OD significantly attenuated the early and late airway responses as shown by the reduction in the area under the curve by 45% (P = 0.016) and 59%, (P = 0.0015), respectively, the increase in eosinophil cationic protein (ECP) by up to 57% (P = 0.021), and airway responsiveness to methacholine by more than 1 doubling dose (P = 0.012). A dose–response relationship was noted, and efficacy was maintained with once per day administration. Conclusions: TPI ASM8 attenuated a broad range of inflammatory and physiological changes after AIC, suggesting that CCR3, IL-3, and GM-CSF also are important targets for the management of asthma.
Classic Descriptions of Disease: With Biographical Sketches of the Authors.
Authors: Ralph Hermon Major
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bacterial and Mycotic Infections of Man
Authors: Arthur L. Bloomfield
Journal: Annals of Internal Medicine (1958)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P2-06-07: StemScreen®, an innovative platform technology for the identification of novel cancer stem cell-directed compounds
Authors: Janice Chen, Hai Li, Marcie A Glicksman, Charles Karan, Christopher Brooks, Eric K Rowinsky
Journal: Cancer Research (2015)

Abstract Cancer stem cells (CSCs) are thought to play significant roles in breast cancer initiation and progression. Conventional therapeutic agents target tumor bulk but spare CSCs, leading to tumor recurrence and relapse. Therefore, drugs that eliminate both tumor bulk and CSCs may represent the most effective treatment strategy for breast cancer. We have developed a proprietary cell-based screen called StemScreen® that permits the rapid testing and identification of novel CSC-directed compounds in a high-throughput manner. StemScreen® takes advantage of a landmark discovery that many cancer cell lines harbor stable populations of CSCs. Our initial studies utilized a breast cancer cell line transfected with a unique expression vector that is only active in the 1-5% putative CSC population. The StemScreen® platform is unique because it allows for screening of compounds within the context of the CSCs’ natural microniche environment and has advantages over traditional drug discovery methods that have been designed to identify compounds that only target tumor bulk, but not CSCs. In an effort to increase the throughput and make the assay compatible with existing compound libraries, we miniaturized the platform to a 384-well format and optimized the line for high-content screening. A series of compound hits identified from screening these cells against smaller libraries of known active compounds as well as larger and more diverse compound libraries will be presented. We are also currently expanding this technology into other tumor types. We believe that this approach represents a major technological advance in oncology drug discovery and that this platform will be instrumental in the discovery of unique new therapies that have a dual effect on CSCs and non-CSC tumor bulk. Citation Format: Janice Chen, Hai Li, Marcie A Glicksman, Charles Karan, Christopher Brooks, Eric K Rowinsky. StemScreen®, an innovative platform technology for the identification of novel cancer stem cell-directed compounds [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-06-07.
Abstract 4077: Impact of RET/PTC3 oncogene's inflammatory and transformative signaling on tumorigenicity of thyroid and non-thyroid tumorigenic cell lines
Authors: Suresh C. Kari, Laurence C. Eisenlohr
Journal: Cancer Research (2014)

Abstract Rearranged in transformation/ papillary thyroid carcinoma 3 (RET/PTC3 or RP3), is a unique fusion oncogene, responsible for a benign version of PTC. RP3 has an active inflammatory component leading to the secretion of various pro-inflammatory cytokines, however the role of inflammation in development and progression of PTC has not been clearly defined. Facilitating investigation of this issue is our finding that the transforming and inflammatory signals of RP3 can be functionally separated allowing us to study each in isolation. We generated several RP3 mutants ablated in; 1) transformative signaling due to mutation of a tyrosine residue (RP3Y588Fmutant) which prevents the binding of downstream adaptor proteins 2) inflammatory signaling through mutation of binding sites for TRAF2 and TRAF6. Transformation only RP3 mutants grew tumors in immunodeficient and immunocompetent mice, strengthening our hypothesis that the inflammatory component of RP3 is responsible for the benign nature of PTC. To assess the impact of inflammatory RP3 on the progression of different tumors, various thyroid and non-thyroid tumorigenic cell lines were transduced with MSCV_IRES_GFP_RP3 mutants and sorted for GFP expression. With highly immunogenic MC57G cells (C57BL/6 mice), the transforming only mutants developed tumors whereas wild type RP3 along with inflammatory only RP3 were rejected. Inflammation only RP3 mutant also led to slower tumor growth in Renca cell line (Balb/c) demonstrating the effect to be independent of haplotype. We are currently extending the analysis to PTC lines with BRAF and KRAS mutations, which are usually associated with more aggressive tumor profiles without an inflammatory tumor microenvironment. Our data so far suggest that contrary to the contemporary view, inflammation can retard tumor progression. Thus, the RP3 oncogene might be exploited in this regard. Future experiments aim to further characterize the importance of RP3-driven inflammation in tumor growth through continued in vivo and in vitro studies. Citation Format: Suresh C. Kari, Laurence C. Eisenlohr. Impact of RET/PTC3 oncogene's inflammatory and transformative signaling on tumorigenicity of thyroid and non-thyroid tumorigenic cell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4077. doi:10.1158/1538-7445.AM2014-4077
Enhancement and Inhibition of the Growth of Tumor Homoiotransplants by Pretreatment of the Hosts With Various Preparations of Normal and Tumor Tissue<xref ref-type="fn" rid="fn1"><sup>2</sup></xref><xref ref-type="fn" rid="fn2"><sup>3</sup></xref>
Authors: George D. Snell
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Enhancement and Inhibition of the Growth of Tumor Homoiotransplants by Pretreatment of the Hosts With Various Preparations of Normal and Tumor Tissue Get access George D. Snell, Sc.D. George D. Snell, Sc.D. Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 719–729, https://doi.org/10.1093/jnci/13.3.719 Published: 01 December 1952 Article history Received: 31 July 1952 Published: 01 December 1952
Autoantibodies Predict Lupus
Authors: Tracy Hampton
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colorectal cancer. Limitations of trial.
Authors: Richard Peto
Journal: BMJ (2009)

In the NORCCAP trial of colorectal cancer screening in Norway,1 the number of patients screened and the range of intestinal sites examined was too limited for even an apparent fourfold reduction in mortality from rectosigmoid cancer to be reliably detectable by a standard intention-to-treat analysis of overall colorectal cancer mortality. In these circumstances, it seems …
Priorities for the primary prevention of breast cancer
Authors: Graham A. Colditz, Kari Bohlke
Journal: CA A Cancer Journal for Clinicians (2014)

Despite recent calls to intensify the search for new risk factors for breast cancer, acting on information that we already have could prevent thousands of cases each year. This article reviews breast cancer primary prevention strategies that are applicable to all women, discusses the underutilization of chemoprevention in high‐risk women, highlights the additional advances that could be made by including young women in prevention efforts, and comments on how the molecular heterogeneity of breast cancer affects prevention research and strategies. CA Cancer J Clin 2014;64:186–194. © 2014 American Cancer Society.
Learned and unlearned concepts in periodontal diagnostics: a 50‐year perspective
Authors: Gary C. Armitage
Journal: Periodontology 2000 (2013)

Abstract In the past 50 years, conceptual changes in the field of periodontal diagnostics have paralleled those associated with a better scientific understanding of the full spectrum of processes that affect periodontal health and disease. Fifty years ago, concepts regarding the diagnosis of periodontal diseases followed the classical pathology paradigm. It was believed that the two basic forms of destructive periodontal disease were chronic inflammatory periodontitis and ‘periodontosis’– a degenerative condition. In the subsequent 25 years it was shown that periodontosis was an infection. By 1987, major new concepts regarding the diagnosis and pathogenesis of periodontitis included: (i) all cases of untreated gingivitis do not inevitably progress to periodontitis; (ii) progression of untreated periodontitis is often episodic; (iii) some sites with untreated periodontitis do not progress; (iv) a rather small population of specific bacteria (‘periodontal pathogens’) appear to be the main etiologic agents of chronic inflammatory periodontitis; and (v) tissue damage in periodontitis is primarily caused by inflammatory and immunologic host responses to infecting agents. The concepts that were in place by 1987 are still largely intact in 2012. However, in the decades to come, it is likely that new information on the human microbiome will change our current concepts concerning the prevention, diagnosis and treatment of periodontal diseases.
Postlude: A House Call
Authors: James Nash
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Calcified “Sister Mary Joseph” Umbilical Metastasis from Ovarian Cystadenocarcinoma Seen on an MDP Bone Scintigram
Authors: WILLIAM EVANS JOHN, DUTTON JANE, N G CHAAN, ARENDS MARK
Journal: Clinical Nuclear Medicine (2002)

JOHN, WILLIAM EVANS F.R.A.N.Z.C.R.*; JANE, DUTTON F.R.C.R.*; CHAAN, N G F.R.C.R.†; MARK, ARENDS M.R.C.P ath.‡ Author Information
168. EIAV-Based Vectors for the Treatment of Haemophilia A
Authors: Pippa A. Radcliffe, Fraser J. Wilkes, Georgina L. Beard, Susan M. Kingsman, Kyriacos A. Mitrophanous
Journal: Molecular Therapy (2004)

Effective gene therapy for haemophilia necessitates a vector system that is not subject to a pre-existing immune response, has adequate coding capacity, can transduce non-dividing cells at a relevant site and gives long-term expression. Lentiviral-based vector systems are currently the only integrating vector systems that fulfil these criteria for the delivery of Factor VIII. Oxford BioMedica's lentiviral vector system is based on the non-primate lentivirus, Equine Infectious Anaemia Virus (EIAV).